Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.

That increase in survival is seen as a major advance in PAH treatment, which has a five-year survival rate of a little over 40%, and is backed up by functional improvements, including a ...

A retrospective analysis from Israel suggested that markers of poor hydration are linked to increased risks of hypertension ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

The report highlights that smoke and pollution emitted by vehicles on the Pune-Mumbai Expressway—one of western India's ...

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look ...

The water has been classified under Class E, with a dissolved oxygen value of 2.3mg/L and a total coliform bacteria level at ...

Hyperpigmentation is a common skin condition, and there are a number of different treatment options available. Keep reading to learn more about your options, including what to expect from ...